Currently, the treatment of recurrent head and neck squamous cell carcinoma (rHNSCC) is typically accomplished with platinum-based chemotherapeutic agents (Cisplatin, Carboplatin) and targeted therapies with EGFR inhibitors, such as Cetuximab (Erbitux) and Panitumumab (Vectibix); however, the response to these agents is limited because neoplastic cells can become resistant due to a mutation or find a new way to grow, so that the treatment no longer works. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.